Prescription fish oil pill shows big benefit for cardiovascular patients

Biopharma company Amarin is making heart-medicine history this morning with noteworthy clinical trial results of its proprietary, prescription formulation of fish oil. The pill, called Vascepa, significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular problems compared to a placebo. The results upend long-held skepticism in the cardiology community about the medicinal value of omega-3 fatty acids found in fish oil. “This is absolutely the most significant study in the field of cardiovascular risk reduction since the statins were introduced,” said Dr. Matthew Budoff, a cardiologist at UCLA and a Vascepa study investigator.